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BACKGROUND: Brain metastases (BMs) develop by largely unknown mechanisms and cause major morbidity and
mortality in patients with solid tumors. Human cytomegalovirus (HCMV) is frequently detected in tumor tissue from
patients with different cancers. Here, we aimed to determine the prevalence and potential prognostic role of HCMV in
BMs.METHODS:We obtained archived samples of BMs from 41 patients with breast cancer and 37 with colorectal
cancer and paired primary tumor tissues from 13 and 12 patients in each respective group. In addition, primary breast
cancer tissues from 15 patients were included. HCMV proteins were detected with an immunohistochemical
technique andWestern blot. HCMVnucleic acids were detectedwith TaqMan polymerase chain reaction (PCR) assay.
RESULTS: HCMV proteins were abundantly expressed in 99% of BM specimens, and in 12 of 13 (92%) paired primary
breast cancer specimens. All 12 paired colon cancer samples were positive for HCMV proteins. Protein staining was
mainly confined to neoplastic cells. Western blot analysis detected an HCMV-IE reactive protein in 53% of breast
cancer specimens, and PCR detected the presence of HCMV DNA and transcripts in 92% and 80% of samples,
respectively. Patients with high-level expression of HCMV-IE proteins in their tumors had a shorter time to tumor
progression and shorter overall survival. CONCLUSIONS: The prevalence of HCMV proteins and nucleic acids is veryMagnus Bergvalls Foundation, Tore Nilson's Foundation, and Swedish Society for
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Translational Oncology Vol. 7, No. 6, 2014 Human Cytomegalovirus in Brain Metastases Taher et al. 733high in primary andmetastatic tumors andmay drive the development ofmetastatic brain tumors; therefore, this virus
may represent a potential therapeutic target in metastatic cancer.
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Characteristic All (n = 78) Breast Cancer
(n = 41)
Colorectal Cancer
(n = 37)
Age at BM diagnosis, n (%)
≤60 54 (69) 36 (88) 18 (49)
N60 24 (31) 5 (12) 19 (51)
Median (range), years 58 (29-80) 52.5 (30-72) 62.5 (29-80)
Sex, n (%)
Women 58 (74) 41 (100) 17 (46)
Men 20 (26) 0 (0) 20 (54)
Calendar year of primary diagnosis, n (%)
1985 to 1999 40 (51) 19 (46) 21 (57)
2000 to 2009 31 (40) 28 (44) 13 (35)
Missing 7 (9) 4 (10) 3 (8)
Calendar year of BM diagnosis, n (%)
1990 to 1999 19 (24) 8 (19) 11 (30)
2000 to 2004 29 (37) 13 (32) 16 (43)
2005 to 2009 30 (38) 20 (49) 10 (27)
Died during follow-up, n (%)
Yes 73 (94) 36 (88) 37 (100)
No 5 (6) 5 (12) 0
Time from primary diagnosis to BM surgery, months
Median (range) 35.4 (0-170) 44.7 (4.1-170) 34.5 (0-101)
Time from BM surgery to death, months
Median (range) 8.6 (0.4-178) 15.4 (0.7-178) 6.0 (0.4-20.4)
Primary breast cancer, n (%)
ER+ 13 (32)
ER− 16 (39)
PR+ 10 (24)
PR− 11 (27)
HER2+ 8 (20)
HER2− 5 (12)
BM, n (%)
ER+ 9 (22)
ER− 6 (15)
PR+ 3 (7)
PR− 11 (27)
HER2+ 3 (7)
HER2− 3 (7)
Primary colorectal cancer, n (%)
Dukes A 0 (0)
Dukes B 4 (11)
Dukes C 14 (38)
Dukes D 5 (14)Introduction
Brain metastases (BMs) are the most common intracranial neoplasms
in adults and cause major morbidity and mortality in patients with
solid tumors, as the prognosis for these patients is very poor [1]. BMs
develop in approximately 10% to 48% of patients with solid tumors,
but their prevalence is likely higher, as regular screening is not routine
for patients with cancer [1,2]. BMs have been reported in 48% of
patients with lung cancer, 15% of patients with breast cancer, 10% to
15% of patients with testicular cancer, 6% to 10% of patients with
malignant melanoma, and 4% of patients with colorectal cancer [3,4].
The incidence of BMs also appears to be increasing [5,6], probably as
a result of improved overall survival (OS) in patients with cancer [7]
and earlier and more accurate detection with modern neuroimaging
modalities [8]. We recently showed that the incidence of BM in a
Swedish population–based cohort of patients with cancer (National
Patient Registry) doubled between 1987 and 2006 [5]. The incidence
of BM was 9% in men and 7% in women with colorectal cancer and
33% in women with breast cancer [5] in 2006. Median survival after
first admission for BM was 3.2 months in patients with breast cancer
and 2.6 months in those with colorectal cancer. The proportion of
patients surviving 1 year was higher among patients with breast cancer
than among those with colorectal cancer (19% vs 6.7%) [5]. The
increased incidence of BMs may also be explained by insufficient
delivery of drugs across the blood-brain barrier, limiting the efficiency
of systemic chemotherapy for BMs [8]. As patients who are diagnosed
with BMs have a median OS of 4.2 months [9], new treatment
strategies are highly warranted.
The exact mechanism by which BMs develop is unknown [10].
Several risk factors are associated with BMs. These include human
epidermal growth factor receptor 2 (HER2)–positive breast cancer
and triple-negative breast cancer [negative for estrogen receptor α
(ERα), progesterone receptor (PR), and HER2] [11,12], COX-2
expression [13], as well as enhanced expression of integrin αvβ3 [14],
CXCR4/SDF-1 [15], and CD44 [16]. COX-2 expression is thought
to mediate impaired blood-brain barrier functions [13], while
CXCR4/SDF-1, CD44, and integrin αvβ3 are thought to mediate
increased metastatic potential to the brain and promote angiogenesis
[13–16], which may contribute to the development of BM.
Human cytomegalovirus (HCMV) is a β-herpes virus that infects
and establishes latency in most of the world’s populations [17].
Emerging evidence demonstrates that HCMV proteins and nucleic
acids are frequently detected in tissue specimens in very high
prevalence in patients with cancers of different origin, including
colon, breast, prostate mucoepidermoid salivary gland tumors,
medulloblastomas, neuroblastoma, glioblastoma, and rhabdomyosar-
coma [18–23]. Because of its high prevalence in cancer, HCMV may
play an important but not yet well-defined role in the establishment
of several cancer forms. HCMV proteins are known to interfere with
cellular and immunologic functions that may affect tumor biology
[18] in a complex manner. This virus encodes more than 750proteins, of which only about 45 to 57 are estimated to be essential for
viral replication [24,25]. While the functions of many of these
proteins are unknown and HCMV's direct oncogenic properties are
still under debate, this virus clearly has numerous oncomodulatory
and oncogenic mechanisms [18,26].
However, regardless of its potential role in tumor development, the
presence of HCMV in tumors of different origin may offer new
therapeutic strategies. In support of this statement, we recently
demonstrated that anti-viral treatment against HCMV significantly
reduced neuroblastoma growth in an animal model, and combined
treatment with valganciclovir and celecoxib (both acting against
HCMV) reduced tumor growth by 72% in a xenograft model [20].
Furthermore, we observed a remarkably increased survival rate among
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The 2-year survival rate increased from 18% to 70% (n = 40) with
6 months of valganciclovir treatment and to 90% (n = 25) with
continuous treatment (P b .0001). ThemedianOS increased from 13.5
months to 30.1 months and 56.4 months, respectively (P b .0001).
Thus, targeting HCMV in virus-positive tumors may offer new
therapeutic options [27].
Recently, we demonstrated the presence of HCMV proteins and
nucleic acids in 94% of sentinel lymph node metastases of breast
cancer [23]. HCMV protein expression was mainly confined to
tumor cells in both primary tumors and sentinel lymph node
metastases. In this study, we determined the prevalence of HCMV
infection in BMs from colorectal and breast cancers and evaluated the
level of HCMV protein expression in relation to patient survival.Materials and Methods
Clinical Samples
We collected archived paraffin-embedded tissue samples of all
available BMs in patients diagnosed with breast or colorectal cancer
who underwent neurosurgical removal of the tumor at Karolinska
University Hospital (Stockholm, Sweden) during 1990 to 2009.
Patients were selected from the pathology registry based on their
primary diagnosis and localization of a central nervous system tumor
that was surgically removed. Seventy-eight patients were identified;
41 had primary breast cancer and 37 had primary colorectal cancer
(Table 1). Paraffin-embedded tissue sections from corresponding
primary tumors were available from 13 of the patients with breast
cancer and 12 with colorectal cancer (Table 1). In addition, fresh
breast tumor tissues were obtained from surgical specimens of 15
patients who underwent surgery at Akershus University Hospital
(Oslo, Norway) during 2014. We performed a review of medical
records to collect the following information: age and calendar year of
primary cancer diagnosis, clinical cancer characteristics (ER, PR, and
HER2 status and colon cancer stage according to Dukes), and date of
death or date of last clinical follow-up. The Regional Human Ethics
Committees in Sweden and Norway (Nos 2008/628-31 and 577-06-
04148, 06118) approved the study. The tumor diagnosis was
determined at the Pathology Department at Karolinska University
Hospital and confirmed by a pathologist (P.R.) and at Akershus
University Hospital by Professor Torill Sauer.
Immunohistochemical Analyses
Paraffin sections (4 μm) were cut, dewaxed in xylene, and rehydrated
in decreasing concentrations of ethanol (Apoteket Farmaci, Stockholm,
Sweden). HCMV-IE and late proteins were detected in the tumor tissues
by using an immunohistochemical (IHC) technique as previously
described [23,28]. In negative control sections, the primary antibody was
omitted. Cytokeratin and β-catenin served as staining controls. The
following antibodies were used: anti–HCMV-IE and HCMV-LA
antibodies (both from Chemicon, Temecula, CA), anti-cytokeratin
antibody (DakoCytomation, Glostrup, Denmark), and anti–β-catenin
antibody [BD Biosciences (Pharmingen), Stockholm, Sweden]. HCMV-
infected lung tissue sections from a patient with human immunodefi-
ciency virus (HIV) were used as a positive control for staining.
The number of HCMV protein–expressing cells in the tissue
sections was estimated in one tissue section of the tumor specimen for
each antibody (in serial sections). The sections were graded on the
basis of the estimated percentages of IE- and LA-positive cells:negative (0% positive cells), low-grade infection (b50% positive
cells), or high-grade infection (≥50% positive cells). IHC staining was
evaluated and graded by two investigators (A.R. and C.T.); neither
had access to the clinical records of the patients. The results were
confirmed by a pathologist (PR).
TaqMan Polymerase Chain Reaction
To confirm that HCMV nucleic acids were present in the pathologic
sections, DNA was extracted from 12 tissue samples with the PicoPure
DNA Extraction Kit (Applied Biosystems, Branchburg, NJ) according to
the manufacturer’s instructions. Paraffin-embedded tissue sections used
to generate DNA were adjacent to the sections used for IHC and protein
extraction for Western blot analyses, and RNA was extracted from the
same piece of frozen tissue used. In brief, BM tissue sections on slides were
dewaxed in xylene, treated with 99.9% ethanol, and air dried. The
sections were then scraped with a sterilized blade into a tube and digested
with proteinase K in DNA extraction buffer for 24 hours at 65°C.
Samples were heated to 95°C to deactivate the proteinase K. Total RNA
and protein were isolated from 15 frozen breast tumor tissues by using
TRIzol LS protocol, according to the manufacturer’s application manual
(Life Technologies, Stockholm, Sweden). cDNA was synthesized by
using the SuperScript First-Strand Synthesis System for RT-PCR
(Invitrogen, Stockholm, Sweden). Both DNA and cDNA were analyzed
by TaqMan polymerase chain reaction (PCR), performed with a
7900HT fast real-time PCR system (Applied Biosystems) using primers
and probes for the HCMV-IE gene (IE DNA primers: forward primer
sequence, GTGACCCATGTGCTTATGACTCTAT; reverse primer
sequence, CTCAACATAGTCTGCAGGAACGT; probes, reporter
TTGGTCACGGGTGTCTC quencher; IE cDNA primers: forward
primer sequence, TGACGAGGGCCCTTCCT; reverse primer se-
quence, CCTTGGTCACGGGTGTCT; probes, reporter AAGGTGC
CACGGCCCG quencher). RNase P and β2-microglobulin served as the
internal control (Applied Biosystems) as previously described [29].
For quantification and standardization purposes, the viral DNA
copy number in the examined samples was estimated using the first
WHO International Standard for HCMV for nucleic acid amplifi-
cation techniques developed by the National Institute for Biological
Standards and Control (code 09/162; Table S1).
Western Blot Assay
TRIzol LS protocol was used for extraction of total protein from
fresh frozen breast cancer tissues (Life Technologies). Western blot
assay was performed by preparing protein samples in Laemmli
buffer containing 5% β-mercaptoethanol, boiled, and separated by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis with
4% to 12% gels and transferred onto a polyvinylidene difluoride
membrane. The membrane was blocked with 5% non-fat dry milk
dissolved in Tris-buffered saline supplemented with 0.1% Tween
20 and probed with mouse monoclonal anti–HCMV-IE proteins
(11-003; Argene (Verniolle, France) or MAB810R; Millipore,
Stockholm, Sweden, both at 1:1000) or mouse monoclonal
anti–β-actin (NB600-501, 1:3000). After washing in Tris-buffered
saline with 0.1% Tween 20, the membrane was incubated with
anti-mouse IRDye 680RD (1:15000; LI-COR Biosciences,
Hamburg, Germany). Bound antibodies were detected with
ODISSEY CLx Infrared Imaging System (LI-COR Biosciences)
and quantification was performed using the Image Studio Lite
Software (LI-COR Biosciences). All the values below 0.1 were
undetectable and were considered as negative.
Figure 1. Summarizing results for all IHC staining on brain tumor tissues. Results from IHC staining from all brain tumor specimens
including both IE and LA HCMV proteins were plotted in A and B, respectively.
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OS data are presented in graphs as Kaplan-Meier estimates,
calculated from the date of primary tumor diagnosis and BM
diagnosis to the date of death or end of follow-up. Kaplan-Meier
curves were tested for significance with the log-rank test using the
GraphPad Prism program. All statistical hypotheses were two-sided,
and P b .05 was considered significant.
Results
High Prevalence of HCMV Proteins and Nucleic Acids in BMs
and Corresponding Primary Tumor Samples of Breast and
Colorectal Cancer Patients
HCMV-IE proteins were detected in 77 of 78 (99%) archived
metastatic brain tumor specimens, and LA antigens in 73 of 74 (99%;
Figures 1, 2, A and B, and 3, A and B). Both HCMV-IE and
HCMV-LA proteins were also detected in 12 of 13 (92%) primary
breast cancer specimens (Figure 2, G–J,M, and N) and in all primary
colorectal cancer specimens available for analyses (12 of 12 for IE and
11 of 11 for LA; Figure 3, G–J, M, and N). HCMV positive control
tissue analysed by IHC was positive for HCMV (S3). Western blot
detected an HCMV-IE reactive protein in 8 of 15 (53%) frozen
breast tumor tissue samples (Table S1). HCMV-IE DNA and
transcripts were detected by TaqMan PCR in 11 of 12 (92%) and in
12 of 15 (80%) examined tissue samples, respectively. In contrast to
the evident high prevalence of HCMV protein expression in examined
tissue specimens, low copy numbers of CMVDNA and transcripts were
detected in tumor specimens, except in two patients with lowCT values
corresponding to high levels of HCMV transcripts (Table S1). These
observations confirm our previous observations of a discrepancy of the
HCMV DNA and protein detection levels in tumors [20].
HCMV Infection Level in BMs Affects Patient Outcome
We earlier observed that the HCMV infection level was predictive for
outcome in glioblastoma patients [28]. To determine whether the level of
HCMV infection was associated with time to tumor progression and OS
for BM patients, we graded the tissue specimens for HCMV-IE and
HCMV-LA protein expression into low-grade (b50% positive cells) and
high-grade infection (≥50% positive cells) based on the estimated
percentage of HCMV protein–positive cells in the tumor tissue section
(Table 2). One patient was HCMV-IE negative (not included in the
analysis), 28% (22 of 78) of patients had low-grade infections, and 71%
(55 of 78) had high-grade infections (Figure 1A andTable 2).One patient
was negative for HCMV-LA protein expression; 73% (54 of 74) of
patients had low-grade infections, and 26% (19 of 74) had high-grade
infections (Figure 1B and Table 2). The IHC staining results for all of the
BM specimens are summarized in Table 2.For all 78 patients, the median OS after diagnosis of BMs was 8.6
months (range, 0.4-177.8; Table 1). Patients with low-grade HCMV
infection tended to have longer median OS than those with high-
grade infection (13.5 vs 6.9 months; Hazard Ratio (HR), 1.58; 95%
Confidence Interval (CI), 0.97-2.56; P = .064; Figure 4A and
Table 2). Breast cancer patients (n = 41) survived longer than
colorectal cancer patients (n = 37) with BM: OS 15.4 months (range,
0.7-177.8) versus 6.0 months (range, 0.4-20.1; HR, 3.71; 95% CI,
2.13-6.46; P b .0001).
In 25 paired available specimens of primary breast cancer (n = 13)
and colorectal cancer (n = 12), HCMV-IE proteins were detected in
92% of breast cancer specimens and in all primary colon cancer
specimens; high-grade infection was observed in 39% and 75% of
those specimens, respectively (Figures 2M and 3M). Patients with
high-grade HCMV infection in their primary tumors had shorter
median time to BM diagnosis than those with low-grade
HCMV infection (30 vs 65.1 months; HR, 2.93; 95% CI, 1.21-
7.05; P = .016; Figure 4B). These patients also had shorter median OS
than those with low-grade HCMV infection (median, 37.8 vs 81.5
months; HR, 3.57; 95% CI, 1.44-8.87; P = .006; Figure 4C).Hormone Receptor Expression in Breast Cancer Cells Correlates
with HCMV Staining
Hormonal receptor expression (ERα and PR) and HER2 in primary
andmetastatic breast cancers are well-known prognostic markers [30,31].
We obtained staining results for ERα (n = 29) and PR (n = 21) expression
in primary breast cancer from clinical records; ERα expression was
available for 15BMs, and PR expressionwas available for 14 (Table 1); we
performed survival analysis for these well-known prognostic markers and
compared these with results for HCMV grading.
As expected, both tumor aggressiveness and survival data differed
significantly between receptor-positive and receptor-negative breast
cancer cells in specimens of primary tumors and BMs (Figures S1 and
S2). The time to BM was shorter in patients whose tumors had no
ERα expression (median, 30 vs 73.3 months, P = .002) or no PR
expression (median, 30 vs 70.4 months, P = .01) in comparison with
patients whose tumors expressed those receptors. Compared with
receptor-positive patients, receptor-negative patients also had shorter
survival after primary tumor diagnosis (median: 44.9 vs 97.3 months
for ERα, P = .0165, and 37.0 vs 88.1 months for PR, respectively,
P = .003; Figures S1 and S2).
ERα and PR staining results from BMs also showed shorter
survival after diagnosis of the metastasis in patients with ERα- and
PR-negative tumors than in those with receptor-positive tumors
(median: 12 vs 34.8 months for ERα, P = .02, and 12.7 vs 57.5
months for PR, P = .04).
Figure 2. IHC analysis of BMs from breast and primary breast cancers. HCMV proteins were detected in tissue sections of BMs (A–D) and
in primary breast cancer tissues (G, J). HCMV-IE expression is confined to tumor cells in brain tumor specimens (A and B and G and H).
Serial sections of the same tumor show immunoreactivity to HCMV-LA protein in the same tumor area (C and D and I and J). Cytokeratin
was used as an epithelial marker and positive control for tumor cells (E) and β-catenin served as a staining control (K–L). Primary antibody
was omitted as a negative control (F). Scale bars: (A, C, E, F, G, I, and K) 300 μm and (B, D, H, J, and L) 100 μm. Results of IHC staining for
primary breast cancer specimens and BMswere plotted inM and N, respectively. HCMV-IE grade of primary tumor correlates with time to
BM (O) and survival after primary tumor diagnosis (P). HCMV grade of BMs from breast cancers correlates with survival from diagnosis of
BM to death (Q).
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Figure 3. IHC analysis of BMs from colon cancer and primary colon cancer. HCMV-IE expression is confined to tumor cells in BMs
specimens (A and B). Serial sections show immunoreactivity to HCMV-LA protein in the same tumor areas (for BMs: C-D and for primary
colon cancer tissues: I-J). Cytokeratin was used as an epithelial marker and positive control (E) and β-catenin served as a staining control
(K). Primary antibody was omitted as a negative control (F and L). (A, C, E, F, G, I, K and L) 300 μm; (B, D, H and J) 100 μm. HCMV-IE graded
as low, b50% positive cells and high, ≥50% positive cells. Results of IHC staining for primary breast cancer specimens and BMs were
plotted in M and N, respectively. Time to BM (O) as well as survival after primary tumor diagnosis (P) and diagnosis of the BM (Q) were
correlated with HCMV-IE infection grade.
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Table 2. Risk of Death Associated with HCMV Expression in BMs and Primary Tumors
HCMV Expression Grade Positive Cells, n (%)
BM
IE protein (n = 78)
Negative 1 (1.3)
Low grade 22 (28.2)
High grade 55 (70.5)
LA protein (n = 74)
Negative 1 (1.4)
Low grade 54 (72.9)
High grade 19 (25.7)
Colon cancer (primary) (n = 12)
IE protein
Negative 0 (0)
Low grade 3 (25)
High grade 9 (75)
Colon cancer (BM) (n = 37)
IE protein
Negative 0 (0)
Low grade 10 (27)
High grade 27 (73)
Breast cancer (primary) (n = 13)
IE protein
Negative 1 (7.7)
Low grade 7 (53.8)
High grade 5 (38.5)
Breast cancer (BM) (n = 41)
IE protein
Negative 1 (2.4)
Low grade 12 (29.3)
High grade 28 (68.3)
Adjusted for age (as a continuous variable) and primary tumor type at diagnosis of BM.
Figure 4. Correlation of survival time with HCMV-IE grade.
(A) Patients with low-grade HCMV-IE infection in BM samples
have improved survival time from diagnosis of BM to death.
Patients with low-grade HCMV-IE infection in primary colon and
breast cancers have significantly longer time to BM (B) and survival
time from diagnosis of the primary tumor (C).
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and PR staining results, tissue specimens were available for 10 patients
with ERα staining and for 6 patients with PR staining. We found that
the HCMV infection grade correlated with receptor expression status
for both ERα and PR (Figures S1 and S2). Unfortunately, HER2
staining was only available from very few patients, which did not
allow further analysis.
Discussion
HCMV proteins and nucleic acids are highly prevalent in several
different malignancies. This study shows, for the first time, a very
high prevalence of HCMV infection in BMs from both breast and
colorectal cancers using well-established techniques for HCMV
detection in tumor specimens [23,28,32]. HCMV proteins were
detected in 99% (n = 78) of BM samples and also in 92% to 100%
(n = 25) of corresponding primary breast and colorectal cancer
specimens. Western blot detected an HCMV-IE reactive protein in
53% (8 of 15) of frozen breast tumor tissue samples, whereas
quantitative TaqMan PCR confirmed the presence of HCMV nucleic
acids in 80% to 92% of breast tumor samples; the reason for this
discrepancy may be differences in sampling handling, limitations in
the sensitivity of the Western blot assay, and the fact that the HCMV-
positive tumor tissue part is not clearly defined in the frozen samples
that were used for Western blot analysis in this study. Interestingly,
viral protein expression was mainly confined to tumor cells, although
some endothelial cells and inflammatory cells in the tumors were also
HCMV positive.
We further observed that patients who had low-grade HCMV
infection in the primary tumor or the BM had longer time to tumor
progression and longer survival. Patients with low-grade HCMV
infection tended to have longer median OS from BM diagnosis,
13.5 months in patients with low-grade HCMV infection comparedto 6.9 months in those with high-grade infection. Time to tumor
progression was longer in patients with low-grade HCMV infection
(65.1 vs 30 months; HR, 2.93; 95% CI, 1.21-7.05; P = .016), as was
survival after primary diagnosis (81.5 vs 37.8 months; HR, 3.57;
95% CI, 1.44-8.87; P = .006; Figure 4, B and C). Patients with
high-grade infections were also more likely to have low or absent ER
and PR expression, and HCMV hence had similar prognostic value
for breast cancer patients as the well-known prognostic factors ER and
PR for breast cancer [11,12]. These observations imply that HCMV
may represent a prognostic factor for metastatic breast and colorectal
cancers, which merit further evaluation in larger patient cohorts.
Importantly, the presence of HCMV in BMs may also open for new
therapy options for these patients who face a very poor prognosis with
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findings that a low-grade HCMV infection in glioblastoma is
associated with improved survival [28,33] and that anti-viral therapy
against HCMV prevents tumor growth of HCMV-positive xenograft
tumors in animal models [20,21] and indicates strongly improved
survival among glioblastoma patients with HCMV-positive
tumors [27,33].
In further support of the hypothesis that HCMV may be a driving
factor of metastatic cancer, we observed that the grade of HCMV
infection in the primary and metastatic tumors was associated with
patient outcome. Specifically, all patients with low-grade HCMV
infection tended to have higher median OS from BM diagnosis,
13.5 months in patients with low-grade HCMV infection compared
to 6.9 months in those with high-grade infection in the BM. The
HCMV infection grade also correlated with time to tumor
progression and survival after primary diagnosis. Time to tumor
progression was longer in patients with low-grade HCMV infection
(65.1 vs 30 months; HR, 2.93; 95% CI, 1.21-7.05; P = .016), as was
survival after primary diagnosis (81.5 vs 37.8 months; HR, 3.57;
95% CI, 1.44-8.87; P = .006; Figure 4, B and C). Patients with
high-grade infections were also more likely to have low or absent ER
and PR expression, and HCMV hence had similar prognostic value
for breast cancer patients as the well-known prognostic factors ER and
PR for breast cancer.
The fact that 94% of sentinel lymph node metastases of breast
cancer [23] and 99% of BMs of colorectal and breast cancers are
HCMV protein positive, but virus positivity is nearly absent in
healthy surrounding tissue, also implies a viral presence in
metastasis-initiating cells. Such scenario may affect tumor biology
and metastatic processes of breast and colorectal cancers and
suggests a biologic role of HCMV rather than being an
epiphenomenon in metastatic cancer [23]. Viral factors that could
affect epithelial-to-mesenchymal transition pathways known to be
important in metastatic cancer are therefore under investigation in
our laboratory.
In conclusion, we found that HCMV infection is highly prevalent
in BMs of breast and colorectal cancer and in paired primary cancer
specimens, which identifies a novel potential driver of metastatic
cancer development in the brain. Further studies in larger patient
cohorts are needed to further evaluate HCMV as a prognostic marker
for breast and colorectal cancers, to assess the possible role of HCMV
infection in metastatic cancer, and to determine whether HCMV-
targeted therapies have a place in the treatment of metastatic
brain cancer.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2014.09.008.
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